Who we are
The King’s College London Gene Therapy Vector Facility (GTVF) provides comprehensive GMP-grade viral vector manufacturing services. This includes Lentiviral Vector (LV), Retroviral Vector (RV) and Adeno-Associated Viral Vector (AAV) production for early-phase clinical trials, alongside substantial programmes in process innovation, knowledge transfer and training to address critical skills shortages.
In partnership with the Network of Innovation Hubs, our vision is to ensure that the UK capitalises on its outstanding academic medical research to deliver novel gene therapies to patients, providing transformative treatments for currently intractable conditions, and generating a vibrant economic landscape.
The GTVF is run by a large, industry-leading team of >50 people who have extensive experience in delivering end-to-end viral vector manufacture for both academic and commercial clients, with a focus on early-stage clinical trials.

Your partner for comprehensive vector manufacture
The GTVF at a glance:
- One of largest vector suppliers to European clinical trials
- 17+ years of gene therapy manufacturing
- >100 GMP viral vector batches delivered
- 4 active GMP production cleanrooms, more under construction
- Large team of ~50 staff from industry and academia
- Commercial and academic project support
- Focus on early-stage clinical trials
- Support with projects in UK, Europe, USA



Get In Touch
Contact us to discuss your lentiviral vector, retroviral vector, and adeno-associated viral vector GMP manufacturing needs: